203 related articles for article (PubMed ID: 16810113)
1. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment.
Holmes CB; Wood R; Badri M; Zilber S; Wang B; Maartens G; Zheng H; Lu Z; Freedberg KA; Losina E
J Acquir Immune Defic Syndr; 2006 Aug; 42(4):464-9. PubMed ID: 16810113
[TBL] [Abstract][Full Text] [Related]
2. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
[TBL] [Abstract][Full Text] [Related]
3. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.
Lawn SD; Myer L; Edwards D; Bekker LG; Wood R
AIDS; 2009 Aug; 23(13):1717-25. PubMed ID: 19461502
[TBL] [Abstract][Full Text] [Related]
4. Ten years of antiretroviral therapy: Incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohort.
Weissberg D; Mubiru F; Kambugu A; Fehr J; Kiragga A; von Braun A; Baumann A; Kaelin M; Sekaggya-Wiltshire C; Kamya M; Castelnuovo B
PLoS One; 2018; 13(11):e0206796. PubMed ID: 30383836
[TBL] [Abstract][Full Text] [Related]
5. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study.
Podlekareva D; Mocroft A; Dragsted UB; Ledergerber B; Beniowski M; Lazzarin A; Weber J; Clumeck N; Vetter N; Phillips A; Lundgren JD;
J Infect Dis; 2006 Sep; 194(5):633-41. PubMed ID: 16897662
[TBL] [Abstract][Full Text] [Related]
7. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study.
Badri M; Wilson D; Wood R
Lancet; 2002 Jun; 359(9323):2059-64. PubMed ID: 12086758
[TBL] [Abstract][Full Text] [Related]
8. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.
Fox MP; Sanne IM; Conradie F; Zeinecker J; Orrell C; Ive P; Rassool M; Dehlinger M; van der Horst C; McIntyre J; Wood R
AIDS; 2010 Aug; 24(13):2041-50. PubMed ID: 20613459
[TBL] [Abstract][Full Text] [Related]
9. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts.
Yazdanpanah Y; Chêne G; Losina E; Goldie SJ; Merchadou LD; Alfandari S; Seage GR; Sullivan L; Marimoutou C; Paltiel AD; Salamon R; Mouton Y; Freedberg KA
Int J Epidemiol; 2001 Aug; 30(4):864-71. PubMed ID: 11511618
[TBL] [Abstract][Full Text] [Related]
10. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
11. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy.
Dankner WM; Lindsey JC; Levin MJ;
Pediatr Infect Dis J; 2001 Jan; 20(1):40-8. PubMed ID: 11176565
[TBL] [Abstract][Full Text] [Related]
12. Common opportunistic infections and their CD4 cell correlates among HIV-infected patients attending at antiretroviral therapy clinic of Gondar University Hospital, Northwest Ethiopia.
Damtie D; Yismaw G; Woldeyohannes D; Anagaw B
BMC Res Notes; 2013 Dec; 6():534. PubMed ID: 24330921
[TBL] [Abstract][Full Text] [Related]
13. Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling.
Deuffic-Burban S; Losina E; Wang B; Gabillard D; Messou E; Divi N; Freedberg KA; Anglaret X; Yazdanpanah Y
Eur J Epidemiol; 2007; 22(10):737-44. PubMed ID: 17828437
[TBL] [Abstract][Full Text] [Related]
14. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.
Gupta A; Wood R; Kaplan R; Bekker LG; Lawn SD
PLoS One; 2012; 7(3):e34156. PubMed ID: 22479548
[TBL] [Abstract][Full Text] [Related]
15. Natural history of opportunistic disease in an HIV-infected urban clinical cohort.
Moore RD; Chaisson RE
Ann Intern Med; 1996 Apr; 124(7):633-42. PubMed ID: 8607591
[TBL] [Abstract][Full Text] [Related]
16. Incidence of common opportunistic infections in HIV-infected individuals in Pune, India: analysis by stages of immunosuppression represented by CD4 counts.
Ghate M; Deshpande S; Tripathy S; Nene M; Gedam P; Godbole S; Thakar M; Risbud A; Bollinger R; Mehendale S
Int J Infect Dis; 2009 Jan; 13(1):e1-8. PubMed ID: 18602329
[TBL] [Abstract][Full Text] [Related]
17. Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010.
Buchacz K; Lau B; Jing Y; Bosch R; Abraham AG; Gill MJ; Silverberg MJ; Goedert JJ; Sterling TR; Althoff KN; Martin JN; Burkholder G; Gandhi N; Samji H; Patel P; Rachlis A; Thorne JE; Napravnik S; Henry K; Mayor A; Gebo K; Gange SJ; Moore RD; Brooks JT;
J Infect Dis; 2016 Sep; 214(6):862-72. PubMed ID: 27559122
[TBL] [Abstract][Full Text] [Related]
18. Incidence of common opportunistic infections among HIV-infected children on ART at Debre Markos referral hospital, Northwest Ethiopia: a retrospective cohort study.
Melkamu MW; Gebeyehu MT; Afenigus AD; Hibstie YT; Temesgen B; Petrucka P; Alebel A
BMC Infect Dis; 2020 Jan; 20(1):50. PubMed ID: 31948393
[TBL] [Abstract][Full Text] [Related]
19. Low uptake of antiretroviral therapy after admission with human immunodeficiency virus and tuberculosis in KwaZulu-Natal, South Africa.
Murphy RA; Sunpath H; Taha B; Kappagoda S; Maphasa KT; Kuritzkes DR; Smeaton L
Int J Tuberc Lung Dis; 2010 Jul; 14(7):903-8. PubMed ID: 20550776
[TBL] [Abstract][Full Text] [Related]
20. Time to initiation of antiretroviral therapy among patients with HIV-associated tuberculosis in Cape Town, South Africa.
Lawn SD; Campbell L; Kaplan R; Boulle A; Cornell M; Kerschberger B; Morrow C; Little F; Egger M; Wood R;
J Acquir Immune Defic Syndr; 2011 Jun; 57(2):136-40. PubMed ID: 21436714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
